1S70 Stock Chart & Stats
€6.60
€0.15(2.33%)
At close: 4:00 PM EDT
€6.60
€0.15(2.33%)
Day’s Range― - ―
52-Week Range€4.68 - €9.60
Previous CloseN/A
Volume11.00
Average Volume (3M)45.00
Market Cap
€260.35M
Enterprise Value€227.40
Total Cash (Recent Filing)€147.61M
Total Debt (Recent Filing)€63.85M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 05, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding30,255,352
10 Day Avg. Volume81
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.02Price Target Upside339.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.59
Revenue Forecast (FY)€331.08K
Bulls Say, Bears Say
Bulls Say
Strategic Licensing AllianceThe alliance expands Cartesian’s platform beyond ex vivo manufacturing and could reduce development complexity. Access to WestGene’s delivery technology and planned Phase 1 testing may create broader autoimmune pipeline optionality over the next several years.
Extended Funding RunwayAdditional financing gives Cartesian more time to advance clinical programs without an immediate financing requirement. A longer runway can support milestone generation, clinical execution and partnership negotiations, although it does not resolve underlying cash burn.
Low Absolute DebtModest absolute debt limits interest and repayment pressure compared with heavily leveraged peers. This provides some financial flexibility while programs mature, although the benefit is constrained by negative equity and the company’s dependence on external capital.
Bears Say
Severe Revenue ContractionThe sharp revenue decline reflects Cartesian’s pre-commercial status and the absence of a stable product-sales base. Without recurring commercial revenue, funding for development remains dependent on financing, collaborations or other non-operating sources.
Persistent Cash BurnSustained negative operating and free cash flow indicates that clinical development consumes substantial capital without internally funding operations. Similar burn to the prior year suggests limited near-term improvement and continued reliance on external financing.
Negative Shareholders’ EquityNegative equity signals accumulated losses and a strained capital structure, reducing balance-sheet resilience. It can limit financing flexibility and increase dilution or restructuring risk if clinical spending continues before meaningful commercial or partnership cash inflows.
Cartesian Therapeutics News
1S70 FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was €4.68 and its highest was €9.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is €260.35M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 67 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Aug 06, 2026. The company reported €0.399 earnings per share for the quarter, beating the consensus estimate of -€0.761 by €1.16.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.87.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 30,255,352 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of €0.399 in its last earnings report, beating expectations of -€0.761. Following the earnings report the stock price went up 2.878%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in DE:1S70
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€29.02 (339.74% Upside)
€29.02 (339.74% Upside)
Blogger Sentiment
Bullish
DE:1S70 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.07%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
1S70 Stock 12 Month Forecast
Average Price Target
€29.02
▲(339.74% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―